M&A led growth strategy !19 Oct 2022 07:09
I think we are now entering a very exciting period on the Dx front (which was all but written off by many...including me) in addition to the Therapeutics front
With yesterday's unexpected news being the 'first step' in ‘an ambitious M&A led growth strategy' that has been a 'year in the making' I think we can expect more news to follow. What gives Avacta the confidence to commence this ambitions ‘M&A led strategy’ ?
With established distribution secured, it will be of key interest to see which products we now launch/leverage through this channel. There would appear to be a much a larger strategy at play with much of the details not yet known.
With good AVA6k data leading to further significant incoming funds (cold be multiple deals), it would be the perfect time to commence an M&A led Dx growth strategy!
This is a seriously exciting times to be holding this share.
Alastair Smith, Chief Executive Officer of Avacta, commented:
"This acquisition will add an established distribution channel to Avacta with three decades of customer relationships and deep market knowledge to drive future product development, strategy and growth. It is the landmark first step in our ambitious M&A-led growth strategy for Avacta's diagnostics division that has been a year in the making.
"Our vision is to build an integrated, differentiated, global reach IVD business serving professionals and consumers, that uses the benefits of its Affimer® platform to differentiate immunodiagnostic products in a competitive market. This is a transformational moment for Avacta Diagnostics, adding a well-established route to market for existing and future in-house and acquired products in the UK and across several key European markets.
Sign In
Follow the stocks
